First Time Loading...

Oncternal Therapeutics Inc
NASDAQ:ONCT

Watchlist Manager
Oncternal Therapeutics Inc Logo
Oncternal Therapeutics Inc
NASDAQ:ONCT
Watchlist
Price: 8.27 USD -2.48%
Updated: Apr 30, 2024

Oncternal Therapeutics Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Oncternal Therapeutics Inc
Revenue Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Revenue Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Oncternal Therapeutics Inc
NASDAQ:ONCT
Revenue
$785k
CAGR 3-Years
-39%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Revenue
$54.3B
CAGR 3-Years
6%
CAGR 5-Years
11%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Revenue
$27.1B
CAGR 3-Years
3%
CAGR 5-Years
4%
CAGR 10-Years
9%
Amgen Inc
NASDAQ:AMGN
Revenue
$28.2B
CAGR 3-Years
4%
CAGR 5-Years
3%
CAGR 10-Years
4%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Revenue
$9.9B
CAGR 3-Years
17%
CAGR 5-Years
26%
CAGR 10-Years
23%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Revenue
$13.1B
CAGR 3-Years
16%
CAGR 5-Years
14%
CAGR 10-Years
20%

See Also

What is Oncternal Therapeutics Inc's Revenue?
Revenue
785k USD

Based on the financial report for Dec 31, 2023, Oncternal Therapeutics Inc's Revenue amounts to 785k USD.

What is Oncternal Therapeutics Inc's Revenue growth rate?
Revenue CAGR 3Y
-39%

Over the last year, the Revenue growth was -47%. The average annual Revenue growth rates for Oncternal Therapeutics Inc have been -39% over the past three years .